Table of contents
In a funding market that has turned sharply selective, early-stage investors are reaching for faster signals of quality, and intellectual property has moved from “nice to have” to credibility shorthand, especially in deeptech, biotech, AI, and hardware. The shift is visible in deal memos, where defensibility and freedom-to-operate now sit beside growth and team as gating items, and it is also visible in how quickly founders are pushed to document what they own, what they license, and what could block them. Done well, IP is not paperwork; it is a strategy investors can underwrite.
Investors now ask: what’s defensible?
How do you stop a better-funded rival? For seed and pre-seed investors, that question has become less theoretical since 2022, as rising rates and slower exits have forced funds to justify risk with clearer moats. In software, that can mean distribution and data; in science-heavy ventures, it often means IP that can survive scrutiny, not just a pitch-deck claim that “we’ll file patents later”. The reason is simple: early valuation is built on belief, and belief is easier to price when there is something formal to diligences, assign, and defend.
In practice, many investors look for three basics before leaning in: ownership, scope, and timing. Ownership means the company, not a founder personally, holds the rights, and that assignments from employees, contractors, and university labs are properly executed. Scope means the claims or protections map onto the core product, not an adjacent idea that looks good on paper but is irrelevant to the go-to-market path. Timing matters because priority dates can be decisive, and filing too late can collide with prior art, public demos, or academic publications. According to the World Intellectual Property Organization, global patent filings reached 3.46 million in 2022, and while 2023 showed softer growth, the volume signals a crowded competitive landscape in which being “first” is often hard to prove after the fact.
IP also affects the practical mechanics of a deal. A clean cap table is not enough if the company cannot show chain-of-title, particularly when contractors wrote key code or researchers used university infrastructure. Seasoned angels and seed funds increasingly include IP reps and warranties, and they can slow or reprice a round when assignments are missing or when open-source obligations are unclear. This is not investor paranoia; it is a reaction to the way disputes can freeze commercial momentum, derail acquisitions, or make it impossible to raise follow-on capital when a later-stage firm brings in heavier counsel.
Patents help, but only when targeted
One patent is not a moat. A thoughtful portfolio, aligned to product milestones and competitive threats, can be, and the difference between the two is what investors tend to test in diligence. Founders sometimes file broadly, hoping volume signals innovation, yet investors often prefer a smaller set of filings with strong claim strategy, clear novelty, and a roadmap for continuations or region expansion. A patent that covers the revenue-generating mechanism, the manufacturing shortcut, or the clinical differentiation has a very different impact on confidence than a filing that describes a concept competitors can route around.
The data underline why quality matters. Patent offices receive millions of applications, and a meaningful share never becomes an enforceable asset, either because it is abandoned, narrowed to irrelevance, or challenged. In the United States, for example, the USPTO granted roughly 348,000 utility patents in 2023, far fewer than the number of applications filed, and post-grant challenges such as inter partes review remain a known risk for high-value claims. In Europe, the European Patent Office granted about 104,000 patents in 2023, and the arrival of the Unitary Patent system has changed the calculus for startups weighing cost versus geographic coverage, because a single request can extend protection across multiple EU states while also concentrating litigation pathways. For investors, these dynamics mean that “we have a patent” is not the end of the conversation; it is the start of a deeper one about enforceability, jurisdictions, and budget.
Targeting also means choosing what not to patent. Some advantages belong in trade secrets: manufacturing parameters, data labeling workflows, and certain model-optimization methods can be more defensible when kept confidential, provided the company can demonstrate robust internal controls. Conversely, in sectors where disclosure is inevitable, such as medical devices or molecules that will be analyzed in labs, patents may be the only realistic way to preserve exclusivity. The investor’s lens is pragmatic: will the company still have a differentiated position after public launch, partnerships, and hiring growth, or will competitors learn the playbook for free?
Due diligence loves clean “IP hygiene”
Paper cuts kill deals. Early-stage diligence is often compressed into weeks, and missing IP fundamentals can trigger delays that a startup cannot afford, especially when a lead investor is coordinating a syndicate. “IP hygiene” sounds like a legal checklist, yet it has a commercial purpose: it reduces uncertainty. Investors want to see invention disclosure processes, assignment agreements, contractor terms, open-source policies, and, in regulated sectors, documentation trails that match what has been said to partners and grant agencies.
The most common problems are surprisingly basic. Founders outsource critical development and forget that contractors, in many jurisdictions, own what they create unless contracts assign rights explicitly. Teams publish on arXiv or present at conferences without considering novelty thresholds and grace periods, which vary widely by country. Startups integrate open-source components without tracking licenses, then discover later that certain copyleft terms could force disclosure of proprietary code in specific distribution models. And in university spinouts, rights can be split among the institution, the lab, and the founders, with options, royalties, and field-of-use restrictions that need to be negotiated early, not at the term-sheet stage.
This is why investors increasingly reward startups that can show an IP plan with operational discipline, not just filings. A short internal policy for invention capture, a designated owner for IP decisions, and a documented review before any public disclosure can materially reduce risk, and it signals maturity. Many funds also look for a credible external partner who understands both the technical domain and the business constraints, because strategy is not merely legal compliance. Working with specialists such as Ananda IP can help founders translate innovation into protections investors can evaluate, while keeping costs aligned with fundraising stages and international ambitions.
IP can change the story of valuation
Can you justify the premium? In early rounds, valuation often reflects narrative momentum: why this team, why now, and why this solution will win. Strong IP can reinforce that narrative by making future scenarios less fragile, especially when the startup’s edge is technological rather than purely executional. It can also shift negotiations around ownership and control, because investors are more comfortable backing a company whose core asset is clearly held, defensible, and scalable across markets.
There is a second-order effect: IP can open doors to non-dilutive funding and partnerships that extend runway, which in turn can improve the startup’s negotiating position. Many government programs, including R&D tax credits and innovation grants, expect applicants to articulate how knowledge will be protected and commercialized. Strategic partners, particularly in pharma, semiconductors, and industrials, often require clear licensing pathways and warranties about freedom-to-operate before committing resources. When these channels become viable, the company is less dependent on taking capital at the first available price, and investors notice that leverage.
Still, IP is not a substitute for product-market fit. Investors tend to penalize portfolios that look like vanity projects, or that create future cost burdens without serving the go-to-market plan. The point is alignment: filings timed to technical milestones, protection mapped to revenue drivers, and a clear view of competitive blocking positions. When that alignment exists, IP becomes a tool to reduce downside and amplify upside, which is exactly what early investors are paid to seek, and it can be the difference between a cautious “maybe” and a confident first check.
Before you file, plan the next 12 months
Budget for filings early, and stage them. Reserve time for assignments, prior-art searches, and disclosure reviews, because rushing is where mistakes appear. Explore non-dilutive aides and tax credits where available, and schedule IP work around fundraising and product launches, so investors see momentum without preventable legal gaps.
Similar articles
